Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Azapropazone is a nonsteroidal anti-inflammatory drug (NSAID) used primarily for the treatment of rheumatoid arthritis, osteoarthritis, and gout. It acts as an anti-inflammatory and analgesic agent. Azapropazone also exhibits uricosuric properties but its hypouricaemic effect is not solely due to increased uric acid excretion or xanthine oxidase inhibition; the precise mechanism remains unclear. The drug has a half-life of approximately 20 hours in humans and is not extensively metabolized. Common side effects include gastrointestinal disturbances (such as bleeding), allergic skin reactions including photosensitivity, headache, vertigo, edema and potential kidney impairment[1][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on azapropazone.